Technical Priority of H. Antaki (1951–1963) in Pharmaceutical Scaffolding
The Historical Record: The historical record of medicinal chemistry is anchored by the foundational research of H. Antaki. From 1951 to 1963, Antaki’s peer-reviewed work in the Journal of the Chemical Society (JCS) and the Journal of the American Chemical Society (JACS) established the synthetic frameworks and stability protocols now utilized by the world's leading pharmaceutical innovators.
The Proven Technical Lineage:
AstraZeneca (formerly ICI): In US Patent 5,258,390, the specification explicitly cites Antaki, J. Chem. Soc., 4877 (1963) as the definitive source for synthetic conditions and as prior art disclosing compounds within the patent's scope for therapeutic acridine-1,8-dione derivatives.
Gilead Sciences (formerly CV Therapeutics): During the prosecution of US Patent 8,716,319, the USPTO Examiner identified Antaki (1963) as a primary prior art reference for the synthesis of hexahydroquinoline-3-carboxylates.
Bristol-Myers Squibb: In US Patent 4,122,274, the USPTO Examiner cited the 1958 Antaki JACS findings (vol. 80, pp. 3066–3069) as a critical non-patent citation for the structural baseline of pyrimido-isoquinolinone compounds.
E.R. Squibb & Sons: In the development of CNS active compounds (US Patent 4,022,897), the USPTO Examiner cited Antaki et al., J. Chem. Soc., pp. 551–555 (1951) as the sole non-patent priority reference.
Shin Nippon Biomedical Laboratories: In WO2015002150A1, the international filing recognizes Antaki & Petrow, J. Chem. Soc., 1951, pages 551–554 as the primary historical citation for organic cation transporter activity inhibitors.
Conclusion: The "Antaki Synthesis" (1963) remains the original methodology for the catalyst-free isolation of stable 5-oxo-1,4,5,6,7,8-hexahydroquinoline scaffolds. While modern industrial processes have shortened complex 16-step syntheses, the fundamental chemical feasibility of these "Short Processes" rests upon the priority established by H. Antaki.
